Viewing nowEmpogagen 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Samchundang Pharmaceutical Co., Ltd.

MFDS item code 202102077 · Approved 2021.03.05 · Insurance code 651206190
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is a treatment to help adults with type 2 diabetes manage their blood sugar levels effectively when used alongside dietary and exercise regimens. It can be administered alone but is typically used in combination with other diabetes medications, such as metformin, when blood sugar control is inadequate. For instance, if blood sugar control is insufficient with metformin monotherapy, this medication can be added to enhance therapeutic effects. Additionally, it may be used alongside insulin or other medications, with careful consideration for patients with cardiovascular disease. Overall, this drug plays a role in improving blood sugar regulation and assisting with diabetes management.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose of this medicine should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This drug should not be used in patients with allergic reactions to the active ingredient or any components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication is also contraindicated for patients with severely impaired kidney function or those on dialysis due to end-stage kidney disease. It contains lactose and should not be given to patients with lactose intolerance or related genetic disorders. In patients with reduced kidney function, this drug should be used cautiously, and dosage adjustments or discontinuation may be required based on kidney function test results. There is limited experience with this drug in some heart failure patients, so it should be used carefully and is not recommended for those with severe heart failure. When used with other medications like insulin or sulfonylureas, monitoring is necessary for the risk of hypoglycemia, with possible dose adjustments required for these medications. During treatment with this drug, precautions should be taken for potential side effects such as hypoglycemia, urinary tract infections, genital fungal infections, and reduced fluid volume. Particularly, serious metabolic disturbances such as ketoacidosis can occur, and immediate consultation with healthcare professionals is necessary upon symptom onset. Elderly patients or those at risk of fluid volume loss should be monitored closely for symptoms of hypotension or dehydration. This drug may have a mild effect on driving or operating machinery, so caution is advised in cases of high hypoglycemia risk. Pregnant or breastfeeding women are advised to avoid this medication, and treatment should be suspended upon confirmation of pregnancy. The safety and efficacy of this drug have not been established for children and adolescents under 18 years of age, hence it should not be used in this population. No specific toxic symptoms have been reported in cases of overdose, but immediate medical attention should be sought. This medication should be kept out of reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's efficacy over time.
Pale yellow, double convex circular film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Samchundang Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.